CrossMark

Fractional Exhaled Nitric Oxide for the Diagnosis of Childhood Asthma: a Systematic Review and Meta-analysis

Songqi Tang[1] · Yiqiang Xie[1] · Conghu Yuan[2] · Xiaoming Sun[3] · Yubao Cui[2,4]

Abstract The gold standard for diagnosing asthma in children is based on clinical history of respiratory symptoms, physical examination, and respiratory function testing. Recent advances indicate that a non-invasive measure of airway inflammation, fractional exhaled nitric oxide (FeNO), provides objective data for use in asthma diagnosis. However, the diagnostic performance of FeNO in children with asthma has not been clearly defined. This systematic review and meta-analysis aimed to evaluate the diagnostic accuracy of FeNO in the clinical determination of asthma in children. Databases of PubMed, the Cochrane Library, EMBASE, MEDION, and Web of Science were searched for relevant articles through March 31, 2016. A bivariate model was used for pooling estimates of sensitivity, specificity, diagnostic odds ratio (DOR), and area under the summary receiver operating curves (SROC) as the main diagnostic measures. In total, eight studies met the inclusion criteria, which included 2933 subjects. The pooled estimates of sensitivity, specificity, and DOR for the detection of asthma in children were 0.79 [95 % confidence interval (CI), 0.64–0.89], 0.81 (95 % CI, 0.66–0.90), and 16.52 (95 % CI, 7.64–35.71). The SROC was 0.87 (95 % CI, 0.84–0.90). In brief, FeNO achieves a moderate diagnostic performance in the detection of asthma in children.

Keywords Fractional exhaled nitric oxide (FeNO) · Childhood asthma · Diagnosis

Introduction

Asthma, the most common chronic disease in children, is characterized by airway hyperresponsiveness and inflammation. The incidence of asthma is increasing worldwide [1]. Accurate detection of asthma is important for effective therapy. The current gold standard for asthma diagnosis is based on clinical history of respiratory symptoms, physical examination, and respiratory function testing [2]. However, these methods are far from perfect. The history of variable respiratory symptoms provided by children is less than objective. Lung function tests are complicated and expensive, and some, such as spirometry and bronchial challenge tests, are relatively invasive and carry a risk of bronchospasm. In addition, these tests do not provide information about airway inflammation.

A non-invasive and readily available technique, fractional exhaled nitric oxide (FeNO), has been developed for asthma diagnosis. Nitric oxide (NO), a signaling molecule in respiratory epithelial cells [3], functions as a vasodilator and bronchodilator in the lungs and serves a protective role in the asthma response. NO synthase enzymes, induced by inflammatory cytokines, mediate the synthesis of NO. NO is detectable in exhaled breath by a chemiluminescence analyzer; much evidence indicates that NO is increased in asthma. Similarly, some studies have demonstrated that FeNO is

Songqi Tang and Yiqiang Xie contributed equally to this work.

✉ Yubao Cui
  ybcui1975@hotmail.com

1 College of Traditional Chinese Medicine, Hainan Medical University, Haikou 571199, China

2 The Third People's Hospital of Yancheng, Affiliated Yancheng Hospital, School of Medicine, Southeast University, Yancheng 224001, Jiangsu Province, People's Republic of China

3 School of Preclinical Medicine, Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, People's Republic of China

4 Department of Clinical Laboratory, The Third People's Hospital, Affiliated Yancheng Hospital, School of Medicine, Southeast University, No. 299 at Jiefangnan Road, Yancheng 224000, Jiangsu Province, People's Republic of China

Springer

elevated in children with asthma compared to those without asthma. Further, the FeNO level reflects the amount of eosinophilic airway inflammation [4]—a key pathological feature of asthma.

FeNO testing is relatively easy for school-aged children, and even preschool-aged children, to perform [5]. Initially used in the 1990s and approved for clinical use in 2003, FeNO testing has been widely applied in the diagnosis of asthma in children [6]. Given its relatively convenient and non-invasive measurement, FeNO has been highlighted as a biomarker in recent years to quantitatively evaluate airway inflammation. Indeed, evidence of the diagnostic efficacy of FeNO is accumulating [7–9]. However, individual studies have yielded insistent or conflicting findings [10, 11], possibly due to limitations associated with individual studies. Further, the FeNO level can be influenced by a number of factors that may affect its diagnostic accuracy. A meta-analysis of 25 studies with a total of 3983 subjects showed that FeNO is a promising marker for the diagnosis of asthma in all populations [12]. However, more recent studies need to be considered. To our knowledge, there is no meta-analysis focused on the diagnostic value of FeNO for asthma exclusively in children.

Thus, to shed light on contradictory results and focus on a pediatric population, we performed a systematic review and meta-analysis of current research reports to assess the performance of FeNO in the diagnosis of childhood asthma. Our findings have implications for the use of FeNO testing in pediatric clinical practice.

Methods

Literature Search and Study Identification

We performed a literature search of relevant databases including PubMed, the Cochrane Library, EMBASE, MEDION, and Web of Science to identify eligible studies published through March 31, 2016. Various combinations of medical subject headings (MeSH) and non-MeSH terms were used, as follows: fractional exhaled nitric oxide, FeNO, and asthma. In addition to published studies in these electronic databases, a manual search of related reports from major annual meetings in the field of pediatrics and reference sections of studies and all relevant reviews was also performed. Studies were restricted to English-language, peer-reviewed publications.

Inclusion criteria for eligible studies were as follows: (1) diagnosis accuracy test design; (2) the index test was FeNO; (3) study subjects were limited to children, and the minimum number was 10; and (4) a two-by-two contingency table could be constructed from data presented by the study. Studies were excluded if they met the following criteria: (1) studies conducted on animals or in vitro systems; (2) the article was a review, case report, or editorial comment; (3) studies on the monitoring impact of FeNO in managing asthma in children; and (4) studies containing overlapping participants. Notably, articles by the same author or research group were included only when a different sample of patients was used. Two investigators (Songqi Tang and Yiqiang Xie) independently performed the literature search and study identification according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [13]. Any disagreement was resolved by discussion with the other three reviewers (Conghu Yuan, Xiaoming Sun, and Yubao Cui).

Quality Assessment

To assess the quality of each included study, we used the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool [14]. Briefly, QUADAS-2 comprises four key domains: patient selection, index test, reference test flow of patients through the study, and the timing of the index and reference tests (flow and timing). These four domains were used for evaluating the risk of bias, and the first three were applied to assess applicability. According to the investigators' answers for all signaling questions in each domain, risks of bias were graded as "low risk," "high risk," or "unclear risk." As for applicability concerns, review authors were supposed to document relevant information and then to assess their concerns if the study matched the review question. Similarly, concerns of applicability were rated as "low risk," "high risk," or "unclear risk." A standardized table and figure, recommended by the QUADAS-2 official website, were used to display the summarized results of the QUADAS-2, with numbers of studies observed with low, high, or unclear risk of bias or applicability concerns for each domain.

Data Extraction

Characteristic information of included studies were extracted, including published year, country, study design, blindedness, number of study subjects, FeNO measurement standard, online measurement, reference standard for the diagnosis of asthma, and cut-off value of FeNO in each study. Absolute numbers of true positive (TP), false positive (FP), false negative (FN), and true negative (TN) were also extracted.

Diagnostic Measures Combination

The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), diagnostic score, and area under the summary receiver operating curve (AUSROC) with the corresponding 95 % confidence interval (CI) were obtained by a bivariate binomial mixed model [15]. The sensitivity, specificity, DOR, and AUSROC were considered as the major outcomes in this study.

Heterogeneity

A Cochrane-Q test of heterogeneity was performed using inconsistency index, I^2, as a measure to illustrate the percentage of the total variability in effect estimates among trials that is caused by heterogeneity instead of chance [16]. A value of I^2 more than 50 % was defined as heterogeneity. A two-sided p value <0.05 indicated statistical significance.

Diagnostic Threshold Effects

Since the cut-off values were different among the included studies, diagnostic threshold effects were inspected [16]. The summary receiver operating curve (SROC) was visually evaluated at first. A Spearman correlation analysis was used to assess the heterogeneity derived from diagnostic threshold effects.

Meta-regression Analysis

To identify the sources of heterogeneity among studies, meta-regression analysis was carried out [16]. Possible sources of heterogeneity including published year, country, study design, blindness, number of study subjects, FeNO measurement standard, online measurement, reference standard for the diagnosis of asthma, and cut-off value of FeNO in each study were included in the analysis. Other sources were not included because of data insufficiency in at least one study.

Publication Bias

Deeks' funnel plot asymmetry analysis was performed to identify the publication bias [17]. Briefly, the Deeks funnel plot was a scatter plot of the inverse of the square root of effective sample size [1/root (ESS)] against the ln (DOR).

Fagan's Nomogram Analysis

The Fagan nomogram plot comprised three vertical axes [18]. The left axis represented the pre-test probability, which was derived from the prevalence in each included study. Another axis in the middle displayed the likelihood ratio showing the extent to which the index could raise or lower the probability of having the disease. The right vertical axis signified the post-test probability of patient's probability of having the positive or negative results of the reference standard test after the index test result was known.

Bivariate Box Plot

With logit specificity and logit sensitivity as horizontal axis and vertical axis, respectively, a bivariate box plot was applied to assess the distributional properties of sensitivity against specificity and investigate possible outliers [19].

Data Synthesis and Statistical Analysis

Data synthesis and most statistical analyses were undertaken by STATA software version 12.0 (College Station, TX, USA) apart from the Meta-regression analysis by Meta-Disc version 1.4 (Clinical Biostatistics Unit, Hospital Ramon y Cajal, Madrid, Spain).

Results

Literature Search and Quality of Studies

The initial search yielded 359 citations from PubMed, the Cochrane Library, EMBASE, MEDION, and Web of Science. Since the search strategy was relatively broad, most of the results were not eligible. After screening on the basis of title and abstract, 62 studies were excluded for various reasons, such as irrelevant topic, different data design, and insufficient sample size. Following full-text assessment, eight studies met the pre-defined inclusion criteria and were included in this systematic review and meta-analysis [20–27]. Figure 1 shows the procedure for inclusion. Characteristics of the included studies and patients' baseline demographics are displayed in Table 1.

Among the eight trials published from 2009 to 2015, three trials were prospective and the other five were retrospective. Four studies were conducted in Asian countries (China and Korea), while the remaining four were conducted in European countries (Israel, Norway, Spain, and Poland). The sample size of each study ranged from 88 to 1651 patients. For these included children, FeNO was measured in accordance with the American Thoracic Society (ATS) or European Respiratory Society guidelines. FeNO values were obtained using online nitric oxide monitors and expressed as parts per billion (p.p.b.). Two studies reported that the physicians providing the asthma diagnosis were blinded to the FeNO results [20, 24]. All the trials used a combination of symptoms, spirometry, bronchial provocation test results, and bronchial dilation test results as the reference standard, except one study by Yao et al. that used symptoms and spirometry only. In addition, various cut-off values with the highest Youden index (sensitivity + specificity − 1) were different among the included studies. The count data for primary studies including true positive (TP), false positive (FP), false negative (FN), and true negative (TN) were extracted and presented in Table 1.

The criteria of Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2), which is an updated evaluation tool for the systematic review and meta-analysis of diagnostic test accuracy, identified the quality conditions of the included

**Fig. 1** Flow chart of search and selection of eligible studies. *n* number of studies

Table 1 Characteristics of the included studies and patients' baseline demographics

Study	Sivan et al.	Sachs-Olsen et al.	Yao et al.	Pérez Tarazona et al.	Woo et al.	Jerzyńska et al.	Zhu et al.	An et al.
Year published	2009	2010	2011	2011	2012	2014	2015	2015
Country	Israel	Norway	China	Spain	Korea	Poland	China	China
Study design	Prospective	Retrospective	Prospective	Retrospective	Prospective	Retrospective	Retrospective	Retrospective
Blinded	Yes	NA	NA	NA	Yes	NA	NA	NA
Number of patients (*n*)	113	227	1651	144	245	389	109	88
FeNO measurement	According to ATS/ERS	According to ATS/ERS	According to ATS/ERS	According to ATS/ERS	According to ATS/ERS	According to ATS/ERS	According to ATS/ERS	According to ATS/ERS
Online	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Reference standard	Symptoms, spirometry, bronchial provocation test, and bronchial dilation test	Symptoms, spirometry, and bronchial provocation test	Symptoms and spirometry	Symptoms, spirometry, and bronchial provocation test	Symptoms, spirometry, and bronchial provocation test	Symptoms, spirometry, and bronchial dilation test	Symptoms, spirometry, and bronchial provocation test	Symptoms, spirometry, and bronchial provocation test
Cut-off value of FeNO (p.p.b.)	19	15.6	28	19	22	23	25.5	22.75
TP	59	11	45	52	95	51	71	54
FP	5	12	466	11	10	151	1	18
FN	10	20	25	5	72	6	13	4
TN	39	184	1082	76	68	181	24	12

Abbreviations: *ATS* American Thoracic Society, *ESC* European Respiratory Society, *FeNO* fractional exhaled nitric oxide, *FN* false negative, *FP* false positive, *NA* not available, *p.p.b.* parts per billion, *TN* true negative, *TP* true positive

studies (Table 2 and Fig. 2). The quality evaluation was performed independently by two investigators.

Data Synthesis of Diagnostic Accuracy

In total, 2933 children from eight trials were included in this systematic review and meta-analysis. With a bivariate model, diagnostic performances of FeNO in asthmatic children were pooled and are summarized in Table 3.

The combined estimates of sensitivity, specificity, and DOR for the detection of asthma in children were 0.79 (95 % CI, 0.64–0.89), 0.81 (95 % CI, 0.66–0.90), and 16.52 (95 % CI, 7.64–35.71) (Fig. 3 and Table 3). The AUSROC was 0.87 (95 % CI, 0.84–0.90) (Fig. 4). Through graphical examination of the SROC plot, the threshold effect was considered absent, with a Spearman correlation coefficient of 0.50 ($p = 0.21$). The corresponding summary PLR and NLR were 4.20 (95 % CI, 2.38–7.39) and 0.25 (95 % CI, 0.15–0.44), respectively, and the combined diagnostic score was 2.80 (95 % CI, 2.03–3.58) (Table 3).

Fagan's nomogram analysis (Fig. 5) revealed that, with a fixed pre-test probability of 20 % and a pooled PLR of 4.20, the post-test probability was increased to 51 %. Conversely, with a combined NLR of 0.25, the post-test probability was decreased to 6 %.

Meta-regression Analysis

As displayed by the forest plot of the pooled main diagnostic measures (sensitivity, specificity, and DOR) in Fig. 3, the heterogeneity for FeNO in the detection of asthma was significant ($I^2 = 93.10$ %, $p < 0.05$; $I^2 = 97.62$ %, $p < 0.05$; $I^2 = 100.00$ %, $p < 0.05$, respectively). Since the threshold effect was absent as mentioned above, the heterogeneity was not caused by this effect. To identify the sources of heterogeneity of the publication year, country, study design, blind, sample size, reference standard, and cut-off value, meta-regression analysis was performed. None of these factors were obvious sources of heterogeneity.

Bivariate Box Plot for Evaluating the Outliers

To evaluate the distributional properties of sensitivity versus specificity and identify possible outliers of diagnostic results, a bivariate box plot analysis was used. As shown in Fig. 6, data from the study by Sachs-Olsen et al. nearly reached the limit of extreme value, indicating that the study had the potential to be heterogeneous with regard to other studies. In addition, data from three studies (Sivan et al., Woo et al., and Zhu et al.) were mild outliers. The entire shape of the bivariate box plot was symmetrical, indicating that the data were closely within a normal distribution.

Publication Bias

Deeks' funnel plot (Fig. 7) was applied to assess the publication bias. At first, visual evaluation revealed that the plot was a symmetrical funnel shape, indicating that publication bias was likely absent. Further, the p value for the Deeks funnel plot asymmetry test was 0.08. Therefore, publication bias was not identified in this meta-analysis.

Discussion

This systematic review and meta-analysis of eight current diagnostic accuracy studies including 2933 cases provides an overview of the diagnostic performance of FeNO in children with asthma. The findings indicate that the diagnostic accuracy of FeNO in the identification of asthma in children is moderate. As suggested by the ATS, FeNO plays an important role in the diagnosis of asthma, especially in the diagnosis of eosinophilic airway inflammation. Moreover, its predictive value is adequately robust to be used in this area [28], more reliable than peak expiratory flow and spirometry, and even comparable to the bronchial challenge test. Considering the diagnostic performance, relative convenience, and non-invasive procedure of measurement, FeNO is a valid tool in diagnosing asthma in children.

Evidence has demonstrated that the utility of FeNO monitoring in distinguishing children who are more at risk of developing asthma lies in the fact that bronchial inflammation and eosinophilic inflammation are found in children before the diagnosis of asthma [29]. We excluded one study for failing to meet the inclusion criteria of our meta-analysis, but it also supported the diagnostic value of FeNO. This study, by Malmberg et al., indicated that the performance of FeNO was better than impulse oscillometry in detecting asthma among preschool-aged children [30]. Moreover, ROC analysis showed that, compared with diagnosis based on history, FeNO had superior diagnostic accuracy in discriminating between children with probable asthma and healthy controls. As widely known, the AUSROC provides an overall evaluation of diagnostic accuracy. Based on the recommended guideline for the interpretation of AUSROC values [31], the diagnostic utility of FeNO for asthma is moderate [AUSROC 0.87 (95 % CI, 0.84–0.90)]. Further, the DOR index combines sensitivity and specificity; therefore, the higher the value of the DOR, the higher the diagnostic accuracy of the test. Our combined estimates of DOR were 0.79 (95 % CI, 0.64–0.89), indicating a moderate diagnostic value of FeNO in the detection of asthma in children. Indeed, Fagan's nomogram revealed that the testing of FeNO would increase the post-test probability of children having asthma (confirmed by symptoms, spirometry, bronchial provocation test, and bronchial dilation test) from 20 to 51 %. Meanwhile, the probability of having a FeNO-

Table 2 Summary of review authors' ratings of bias risk and applicability concerns for each study

Study	Risk of bias				Applicability concerns		
	Patient selection	Index test	Reference standard	Flow and timing	Patient selection	Index test	Reference standard
Sivan et al	Low	High	Low	Low	Low	Low	Low
Sachs-Olsen et al	Low	High	Low	Low	Low	Low	Low
Yao et al	Low	High	Low	?	Low	Low	Low
Pérez Tarazona et al	High	High	?	Low	Low	Low	Low
Woo et al	Low	High	Low	Low	Low	Low	Low
Jerzyńska et al	Low	High	Low	Low	Low	Low	Low
Zhu et al	High	High	?	?	High	High	Low
An et al	High	High	?	?	High	High	Low

⊕ Low risk　　　⊖ High risk　　　? Unclear risk

negative diagnostic outcome was decreased from 20 to 6 %. According to these findings, FeNO is of moderate value in identifying asthma in children.

A recent systematic review and meta-analysis included 25 studies and 3983 subjects to pool results in determining the effectiveness of FeNO in detecting asthma in different populations [12]. The sensitivity, specificity, and DOR for the entire population were 72 % (95 % CI, 70–74 %), 78 % (95 % CI, 76–80 %), and 15.92 (95 % CI, 10.70–23.68), respectively. The SROC analysis revealed a receiver operating characteristic of 0.88. In subgroup analysis, the DOR for patients using corticosteroids and those for steroid-naive, non-smoking, smoking, chronic cough, and allergic rhinitis patients were 4.47 (95 % CI, 3.39–5.90), 21.40 (95 % CI, 15.38–29.76), 19.84 (95 % CI, 15.63–25.19), 5.41 (95 % CI, 2.97–9.86), 35.36 (95 % CI, 23.90–52.29), and 2.99 (95 % CI, 0.85–10.45), respectively. These results revealed the comparatively good performance of FeNO for the diagnosis of asthma in steroid-naive or non-smoking patients, particularly in chronic cough patients. Though the cases in our analysis were limited to children, the diagnostic estimates of FeNO in our analysis were in line with the entire population

as reported by Guo et al. However, concern has been raised about the univariate model used in separately combining estimates of sensitivity and specificity, either with a fixed- or random-effects model, since it might lead to inaccurate results with the threshold effects and correlation between the two estimates being ignored.

Here, we applied a sophisticated method, the bivariate binomial mixed model, for combining diagnostic estimates. This specialized model utilizes a hierarchical structure of the distribution of data in terms of two levels corresponding to the variation within and between studies, with the two-dimensional nature of diagnostic accuracy being preserved [32]. Considering the significant between-study heterogeneity in our analysis, it is more appropriate to use this model. Additionally, this model takes into account a potential link between sensitivity and specificity and manages the differences in the precision of the two estimates. Last but not least, the bivariate model allows for the effect of covariates that influence the sensitivity and specificity. Notably, this method is at present regarded as the optimal method for acquiring pooled statistics for meta-analysis of diagnostic test accuracy and recommended by the Diagnostic Test Accuracy Working

**Fig. 2** Cumulative bar plot of bias risk and applicability concerns across all studies

Table 3 Summary of the pooled estimates of FeNO in the diagnosis of asthma in children

	Estimates (95 % CI)
Number of included studies	8
Number of subjects	2933
Sensitivity	0.79 (0.64, 0.89)
Specificity	0.81 (0.66, 0.90)
Positive likelihood ratio	4.20 (2.38, 7.39)
Negative likelihood ratio	0.25 (0.15, 0.44)
Diagnostic odds ratio	16.52 (7.64, 35.71)
Diagnostic score	2.80 (2.03, 3.58)
AUSROC	0.87 (0.84, 0.90)

Abbreviations: *ES* estimates, *AUSROC* area under the summary receiver operating curve, *CI* confidence interval

Group of the Cochrane Collaboration and the Agency for Healthcare Research and Quality (AHRQ) [31]. Therefore, our pooled estimates of diagnostic measures should be reliable.

Based on the ATS guidelines, FeNO levels less than 20 p.p.b. are considered below the "negative cut-off," indicating that eosinophilic inflammation and responsiveness to corticosteroids is less likely [28]. On the other hand, FeNO levels greater than 35 p.p.b. represent the "positive cut-off," signifying that eosinophilic inflammation does exist and the responsiveness to corticosteroids is good. Intermediate FeNO between 20 and 35 p.p.b. should be interpreted cautiously based on the clinical context. Among the included studies in our analysis, around 20 p.p.b. appears to be supported as the reasonable cut-off value as was used in relatively recent studies. Sivan


Fig. 4 Summary receiver operating curve of FeNO in the diagnosis of asthma in children. *AUSROC* area under the summary receiver operating curve, *SROC* summary receiver operating curve. *1*: study by Sivan et al.; *2*: study by Sachs-Olsen et al.; *3*: study by Yao et al.; *4*: study by Pérez Tarazona et al.; *5*: study by Woo et al.; *6*: study by Jerzyńska et al.; *7*: study by Zhu et al.; *8*: study by An et al.

et al. reported that children having values of FeNO more than 23 p.p.b. are very likely to have asthma, with a sensitivity of 0.86, specificity of 0.89, and DOR of 46.02 [20]. In a report of a birth cohort, Sachs-Olsen et al. found that 16.6 p.p.b. in children at age 10 was the optimal value in diagnosing current allergic asthma, but not in current non-allergic asthma [21]. The cut-off


Fig. 3 Forest plot of the combined diagnostic estimates of sensitivity, specificity, diagnostic odds ratio of FeNO. *DOR* diagnostic odds ratio, *ES* estimates

Fagan's Nomogram plot

Fig. 5 Fagan's nomogram plot analysis to evaluate the clinical utility of FeNO for the detection of asthma in children. In each plot, a *vertical axis* on the *left* shows the fixed pre-test probability. Using the likelihood ratio in the *middle axis*, a post-test probability (patient's probability of having the disease after the index test result was known) was acquired. With a fixed pre-test probability of FFR of 20 %, the post-test probabilities of having asthma, given positive and negative FeNO results, were 51 and 6 %

Bivariate Boxplot

Fig. 6 The bivariate box plot for evaluating the outliers. 1: study by Sivan et al; 2: study by Sachs-Olsen et al; 3: study by Yao et al; 4: study by Pérez Tarazona et al; 5: study by Woo et al; 6: study by Jerzyńska et al; 7: study by Zhu et al; 8: study by An et al

Deeks' Funnel Plot Asymmetry Test

Fig. 7 Deeks' funnel plot for detecting publication bias. *ESS* effective sample size. *1*: study by Sivan et al.; *2*: study by Sachs-Olsen et al.; *3*: study by Yao et al.; *4*: study by Pérez Tarazona et al.; *5*: study by Woo et al.; *6*: study by Jerzyńska et al.; *7*: study by Zhu et al.; *8*: study by An et al.

value in other studies ranged from 15.6 to 28 p.p.b. However, the Spearman correlation coefficient was 0.50 ($p = 0.21$), implying that the threshold effect was likely absent.

When interpreting FeNO levels in diagnosing asthma, it is necessary to take neonatal history into account. As reported in a study by Ricciardolo et al., a history of neonatal respiratory distress in preterm infants without bronchopulmonary dysplasia might lower the value of FeNO [33]. This finding was in parallel to the results of a study of lower FeNO values in school-aged children with a history of bronchopulmonary dysplasia compared to controls [34]. Meanwhile, Filippone et al. found that, among adolescents with former preterm and bronchopulmonary dysplasia (BPD), former preterm adolescents without BPD, and healthy adolescents, FeNO levels were comparable [35]. Thus, a FeNO value lower than expected warrants caution for interpretation in the clinic since changes may occur in the airway in formerly premature infants with and without a history of BPD.

In addition to its diagnostic value, FeNO is recommended by the ATS as an indicator of medication management [28]. Peirsman et al. investigated the application of FeNO in asthma management with inhaled corticosteroids and leukotriene receptor antagonist medications in children with mild-to-severe asthma and allergic sensitization over a 52-week period. The researchers found that children in the FeNO group (FeNO was used to determine asthma management using a cut-off value of 20 p.p.b.) were observed with less asthma exacerbations over

1 year, compared with those in another group where clinical symptoms, rescue medication use, and the forced expiratory volume in 1 s were used to determine medication management. However, a recent meta-analysis of pediatric trials comparing the use of FeNO with conventional methods to manage asthma (including the studies of Jartti et al.) showed that, although the use of FeNO was associated with a lower frequency of >1 asthma exacerbation in asthma, this management has no superior clinical benefit over the guideline-based method [36].

Our analysis had several limitations. First, the search strategy was restricted to articles published in English, which excluded some non-English literature studies, conference abstracts, and other study design articles. Second, the number of included studies in this systematic review and meta-analysis was relatively small, and the sample size varied widely in different studies. In addition, there was significant heterogeneity observed in the outcomes of sensitivity, specificity, and DOR, but we failed to identify the main source of heterogeneity since the information reported was limited.

Conclusions

Our systematic review and meta-analysis lends support to the view that FeNO is a promising tool for the detection of asthma in children, with moderate diagnostic accuracy. This is the latest meta-analysis assessing the diagnostic value of FeNO for asthma in children exclusively. Notably, however, more clinical trials are warranted to demonstrate its clinical benefits in real-world practice.

References

1. Rao DR, Phipatanakul W (2016) An overview of fractional exhaled nitric oxide and children with asthma. Expert Rev Clin Immunol 12(5):521–530

2. Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen JM, Haahtela T, Hurd SS, Inoue H, de Jongste JC, Lemanske RF Jr, Levy ML, O'Byrne PM, Paggiaro P, Pedersen SE, Pizzichini E, Soto-Quiroz M, Szefler SJ, Wong GW, FitzGerald JM (2015) A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J 46(3):622–639

3. Moncada S, Higgs A (1993) The L-arginine-nitric oxide pathway. N Engl J Med 329(27):2002–2012

4. Alving K, Weitzberg E, Lundberg JM (1993) Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 6(9):1368–1370

5. Hanson JR, De Lurgio SA, Williams DD, Dinakar C (2013) Office-based exhaled nitric oxide measurement in children 4 years of age and older. Ann Allergy Asthma Immuno 111(5):358–363

6. Silkoff PE, Carlson M, Bourke T, Katial R, Ogren E, Szefler SJ (2004) The Aerocrine exhaled nitric oxide monitoring system NIOX is cleared by the US Food and Drug Administration for monitoring therapy in asthma. J Allergy Clin Immunol 114(5):1241–1256

7. Balinotti JE, Colom A, Kofman C, Teper A (2013) Association between the Asthma Predictive Index and levels of exhaled nitric oxide in infants and toddlers with recurrent wheezing. Arch Argent Pediatr 111(3):191–195

8. Paraskakis E, Brindicci C, Fleming L, Krol R, Kharitonov SA, Wilson NM, Barnes PJ, Bush A (2006) Measurement of bronchial and alveolar nitric oxide production in normal children and children with asthma. Am J Respir Crit Care Med 174(3):260–267

9. van der Valk RJ, Caudri D, Savenije O, Koppelman GH, Smit HA, Wijga AH, Postma DS, Kerkhof M, Brunekreef B, de Jongste JC (2012) Childhood wheezing phenotypes and FeNO in atopic children at age 8. Clin Exp Allergy 42(9):1329–1336

10. Elmasri M, Romero KM, Gilman RH, Hansel NN, Robinson CL, Baumann LM, Cabrera L, Hamilton RG, Checkley W, Pura Study Investigators (2014) Longitudinal assessment of high versus low levels of fractional exhaled nitric oxide among children with asthma and atopy. Lung 192(2):305–312

11. Jouaville LF, Annesi-Maesano I, Nguyen LT, Bocage AS, Bedu M, Caillaud D (2003) Interrelationships among asthma, atopy, rhinitis and exhaled nitric oxide in a population-based sample of children. Clin Exp Allergy 33(11):1506–1511

12. Guo Z, Wang Y, Xing G, Wang X (2016) Diagnostic accuracy of fractional exhaled nitric oxide in asthma: a systematic review and meta-analysis of prospective studies. J Asthma 53(4):404–412

13. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700

14. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM, QUADAS-2 Group (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529–536

15. Menke J (2013) Bivariate random-effects meta-analysis of sensitivity and specificity with the Bayesian SAS PROC MCMC: methodology and empirical evaluation in 50 meta-analyses. Med Decis Making 33(5):692–701

16. Devillé WL, Buntinx F, Bouter LM, Montori VM, de Vet HC, van der Windt DA, Bezemer PD (2002) Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2:9

17. Deeks JJ, Macaskill P, Irwig L (2005) The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58(9):882–893

18. Caraguel CG, Vanderstichel R (2013) The two-step Fagan's nomogram: ad hoc interpretation of a diagnostic test result without calculation. Evid Based Med 18(4):125–128

19. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH (2005) Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 58(10):982–990

20. Sivan Y, Gadish T, Fireman E, Soferman R (2009) The use of exhaled nitric oxide in the diagnosis of asthma in school children. J Pediatr 155(2):211–216

21. Sachs-Olsen C, Lødrup Carlsen KC, Mowinckel P, Håland G, Devulapalli CS, Munthe-Kaas MC, Carlsen KH (2010)

Diagnostic value of exhaled nitric oxide in childhood asthma and allergy. Pediatr Allergy Immunol 21(1Pt2):e213–221

22. Pérez Tarazona S, Martínez Camacho RM, Alfonso Diego J, Escolano Serrano S, Talens Gandía J (2011) Diagnostic value of exhaled nitric oxide measurement in mild asthma. An Pediatr (Barc) 75(5):320–328

23. Yao T, Ou L, Lee W, Yeh K, Chen L, Huang J (2011) Exhaled nitric oxide discriminates children with and without allergic sensitization in a population-based study. Clin Exp Allergy 41(4):556–564

24. Woo SI, Lee JH, Kim H, Kang JW, Sun YH, Hahn YS (2012) Utility of fractional exhaled nitric oxide (FENO) measurements in diagnosing asthma. Respir Med 106(8):1103–1109

25. Jerzyńska J, Majak P, Janas A, Stelmach R, Stelmach W, Smejda K, Stelmach I (2014) Predictive value of fractional nitric oxide in asthma diagnosis-subgroup analyses. Nitric Oxide 40:87–91

26. Zhu H, Yu X, Hao C, Wang Y, Yang X, Lu Y, Sun H, Luo W, Lai K (2015) The diagnostic value of the fractional exhaled nitric oxide for cough variant asthma in children. Zhonghua Jie He He Hu Xi Za Zhi 38(5):352–355 **(In Chinese)**

27. An SH, Tian WQ, Li JY (2015) Utility of fractional exhaled nitric oxide in children with asthma. Zhongguo Dang Dai Er Ke Za Zhi 17(8):134–137

28. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin AC, Plummer AL, Taylor DR, American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications (2011) An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 184(5):602–615

29. Pohunek P, Warner JO, Turzíková J, Kudrmann J, Roche WR (2005) Markers of eosinophilic inflammation and tissue remodelling in children before clinically diagnosed bronchial asthma. Pediatr Allergy Immunol 16(1):43–51

30. Malmberg LP, Pelkonen AS, Haahtela T, Turpeinen M (2003) Exhaled nitric oxide rather than lung function distinguishes preschool children with probable asthma. Thorax 58(6):494–499

31. Bae JM (2014) An overview of systematic reviews of diagnostic tests accuracy. Epidemiol Health 36:e2014016

32. Lee J, Kim KW, Choi SH, Huh J, Park SH (2015) Systematic review and meta-analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers—part II. Statistical methods of meta-analysis. Korean J Radiol 16(6):1188–1196

33. Ricciardolo FL, Silvestri M, Pistorio A, Strozzi MM, Tosca MA, Bellodi SC, Battistini E, Gardella C, Rossi GA (2010) Determinants of exhaled nitric oxide levels (FeNO) in childhood atopic asthma: evidence for neonatal respiratory distress as a factor associated with low FeNO levels. J Asthma 47(7):810–816

34. Baraldi E, Azzolin NM, Zanconato S, Dario C, Zacchello F (1997) Corticosteroids decrease exhaled nitric oxide in children with acute asthma. J Pediatr 131(3):381–385

35. Filippone M, Bonetto G, Corradi M, Frigo AC, Baraldi E (2012) Evidence of unexpected oxidative stress in airways of adolescents born very pre-term. Eur Respir J 40(5):1253–1259

36. Lu M, Wu B, Che D, Qiao R, Gu H (2015) FeNO and asthma treatment in children: a systematic review and meta-analysis. Medicine (Baltimore) 94(4):e347